Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
0.400 Biomarker disease BEFREE Persistence of hepatocellular carcinoma risk in hepatitis C patients with a response to IFN and cirrhosis regression. 29377616 2018
Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
0.400 Biomarker disease BEFREE A lower progression to cirrhosis was found in NASVAC group compared to Peg-IFN group. 30133478 2018
Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
0.400 Biomarker disease BEFREE As a result of the exceedingly high cost of DAAs in many countries, IFN-free DAA regimens are mostly reserved to patients with advanced fibrosis or cirrhosis. 26725891 2016
Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
0.400 Biomarker disease BEFREE These patients received 4 weeks of PEG-IFN/RBV (lead-in), followed by response-guided therapy with PEG-IFN/RBV plus BOC (a fixed 44 weeks was indicated in the case of cirrhosis). 27815225 2016
Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
0.400 Biomarker disease BEFREE The results are as follows: (1) both ETV and TDF showed long-term efficacy and safety; (2) PEG IFN-α resulted in a greater decline in HBV DNA levels and a higher rate of HBeAg seroconversion; (3) combination therapy with IFN plus two analogues did not elevate the rate of sustained responses; (4) both ETV and TDF showed efficacy and safety with cirrhosis (ETV especially displayed efficacy and safety with decompensated cirrhosis), and (5) suppression of HCC was observed by ETV and IFN. 26584037 2015
Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
0.400 Biomarker disease BEFREE In patients with HCV genotype 1 (HCV-1), a PEG-IFN/RBV-based regimen with sofosbuvir is highly effective but the presence of cirrhosis and the non-CC IFNL3 genotype have been associated with a poorer response. 25529083 2015
Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
0.400 Biomarker disease BEFREE The recent October 2014 approval of the fixed dose combination (FDC) of the NS5B polymerase inhibitor sofosbuvir (SOF) and the NS5A inhibitor ledipasvir (LDV) for the treatment of treatment-naive and -experienced HCV genotype 1a/1b (HCV-1) has marked a new era of IFN and ribavirin free treatment for chronic hepatitis C. SOF/LDV combination is approved for 12 weeks in treatment-naive patients with and without cirrhosis. 25676581 2015
Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
0.400 Biomarker disease BEFREE The results of the first oral combination of Sofosbuvir and RBV for 12 weeks in genotype 3-infected patients have been rather disappointing with a slightly lower SVR than after 24 weeks of PEG-IFN: around 60%, and only 30% in patients with cirrhosis. 24373074 2014
Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
0.400 Biomarker disease BEFREE The efficacy of peg-IFN plus RBV among HIV/HCV-coinfected patients with cirrhosis is lower than in those without cirrhosis, although this antiviral combination still leads to a substantial rate of SVR in those carrying HCV genotype 3. 22955435 2012
Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
0.400 GeneticVariation disease BEFREE Power and sample size were a priori calculated and 96 consecutive chronic hepatitis C patients (53, genotype 2 and 43, genotype 3) without cirrhosis who were not obese and who achieved a RVR to therapy with peg-IFN-α-2a and ribavirin were enrolled. 22497814 2012
Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
0.400 Biomarker disease BEFREE Full-dose antiviral therapy with PEG-IFN and ribavirin can be safely carried out even in patients with compensated, fully established cirrhosis and portal hypertension. 19849774 2009
Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
0.400 Biomarker disease BEFREE We aimed to assess whether cirrhosis modifies the pattern of PEG-IFN-alpha2b and RBV treatment failure. 19578243 2009
Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
0.400 Therapeutic disease CTD_human These results suggest that IFN-alpha gene therapy is a promising strategy to treat HCC patients who have concomitant liver cirrhosis. 18665156 2008
Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
0.400 Biomarker disease BEFREE Peg-IFN therapy seems to slow down the rate of cirrhosis progression also in HIV/HCV co-infected patients nonresponders to anti-HCV therapy, in comparison with untreated patients. 17802905 2007
Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
0.400 Biomarker disease BEFREE IFN therapy reduces cirrhosis and HCC development. 17107734 2007
Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
0.400 Biomarker disease BEFREE Because PEG-IFN therapy results in a high rate of sustained off-therapy response, patients with advanced fibrosis or cirrhosis but compensated liver disease should not be excluded from PEG-IFN treatment. 17604363 2007
Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
0.400 GeneticVariation disease BEFREE Productive infections have been achieved recently with genotype 2a virus, but cirrhosis and liver cancer are typically associated with genotype 1 HCV, which is more prevalent and relatively resistant to IFN therapy. 16461899 2006
Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
0.400 GeneticVariation disease BEFREE During follow-up, two patients of the control group and three patients of the IFN group developed cirrhosis, and one of the IFN- treated patients progressed to hepatocellular carcinoma. 16012762 2005
Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
0.400 GeneticVariation disease BEFREE We failed to demonstrate any association between -308 TNF-alpha promoter polymorphisms and response to IFN therapy, which was inversely correlated to liver cirrhosis, pretreatment serum HCV RNA levels and genotype 1b by using multivariate analysis. 12834858 2003
Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
0.400 Biomarker disease BEFREE HCV genotype 2a/c, absence of cirrhosis and a low cryocrit (<9%) were predictive factors of high response rate to IFN. 9431896 1997
Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
0.400 GeneticVariation disease BEFREE In a pilot study of long-term treatment, 42 such patients were randomly assigned to 6 million units of interferon alfa 2b (IFN-alpha2b) three times per week for 24 consecutive months (n = 21, 4 with cirrhosis) or to no therapy (n = 21, 3 with cirrhosis). 9398007 1997